The Mechanism in the production of neutralizing autoantibodies against IL-1
| Project/Area Number |
02807207
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
医学一般
|
|---|
| Research Institution | Institute of Clinical Medicine, University of Tsukuba |
|---|
Principal Investigator |
SUZUKI Hiroshi Inst, of Clinical Medicine, Lecturer University of Tsukuba., 臨床医学系, 講師 (00179243)
|
|---|
| Project Period (FY) |
1990 – 1991
|
| Project Status |
Completed (Fiscal Year 1991)
|
| Budget Amount *help |
¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 1991: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1990: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Keywords | interleukin 1 / Anti-IL-1 autoantibody / Anti-cytokine autoantibody / Interleukin 6 / ILー1 / ILー6 / 自己抗体 |
|---|
| Research Abstract |
In order to investigate the mechanism by which anti-IL-1alpha autoantibodies develop, we first examined immunological characteristics of the autoantibodies. The affinity of the autoantibodies was extremely high(Kd-10^<-11> l/M)and neutralizing activities of the autoantibodies were proportional to the binding activities of the autoantibodies to IL-1 alpha, suggesting that the autoantibodies recognize very restricted portions of IL-1 alpha molecules and are against IL-1 alpha itself, but not to some other molecules cross-reactive to IL-1 alpha. The fluctuations of the titers of anti-IL-1 alpha autoantibodies during clinical course of rheumatoid arthritis further suggested that the development of the autoantibodies resulted from immune response to IL-1 alpha present in synovial tissues of active rheumatoid arthritis. We have next tried to make monoclonal anti-IL-1alpha autoantibodies by fusion of a mouse-human heterohybridoma cell line to EB-virus transformed B cell lines producing anti-IL-lalpha antibodies, but have not yet succeeded in the project. During the investigation of other anti-cytokine autoantibodies, we found anti-IL-6 autoantibodies which were observed at increased frequency in patients with systemic sclerosis(about 17 %)compared with normal subjects(about 2 %). Anti-IL-6 autoantibodies have several different characteristics from anti-IL-1alpha autoantibodies. Anti-IL-6 autoantibodies are present as complex with IL-6 in vivo and showed IL-6 activity, suggesting the roles of the autoantibodies as carriers of IL-6 in vivo.
|
Report
(3 results)
Research Products
(23 results)
